Lonza Group Ltd (LZAGY)
57.93
+2.24
(+4.02%)
USD |
OTCM |
Apr 23, 10:49
Lonza Group Price to Book Value: 3.712 for April 23, 2024
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| April 22, 2024 | 3.569 |
| April 19, 2024 | 3.534 |
| April 18, 2024 | 3.566 |
| April 17, 2024 | 3.672 |
| April 16, 2024 | 3.694 |
| April 15, 2024 | 3.720 |
| April 12, 2024 | 3.734 |
| April 11, 2024 | 3.816 |
| April 10, 2024 | 3.761 |
| April 09, 2024 | 3.880 |
| April 08, 2024 | 3.94 |
| April 05, 2024 | 3.883 |
| April 04, 2024 | 3.844 |
| April 03, 2024 | 3.847 |
| April 02, 2024 | 3.763 |
| April 01, 2024 | 3.849 |
| March 28, 2024 | 3.839 |
| March 27, 2024 | 3.809 |
| March 26, 2024 | 3.772 |
| March 25, 2024 | 3.749 |
| March 22, 2024 | 3.778 |
| March 21, 2024 | 3.722 |
| March 20, 2024 | 3.70 |
| March 19, 2024 | 3.466 |
| March 18, 2024 | 3.442 |
| Date | Value |
|---|---|
| March 15, 2024 | 3.433 |
| March 14, 2024 | 3.488 |
| March 13, 2024 | 3.436 |
| March 12, 2024 | 3.347 |
| March 11, 2024 | 3.351 |
| March 08, 2024 | 3.384 |
| March 07, 2024 | 3.402 |
| March 06, 2024 | 3.295 |
| March 05, 2024 | 3.294 |
| March 04, 2024 | 3.354 |
| March 01, 2024 | 3.385 |
| February 29, 2024 | 3.351 |
| February 28, 2024 | 3.372 |
| February 27, 2024 | 3.385 |
| February 26, 2024 | 3.352 |
| February 23, 2024 | 3.370 |
| February 22, 2024 | 3.348 |
| February 21, 2024 | 3.313 |
| February 20, 2024 | 3.304 |
| February 16, 2024 | 3.322 |
| February 15, 2024 | 3.342 |
| February 14, 2024 | 3.359 |
| February 13, 2024 | 3.182 |
| February 12, 2024 | 3.264 |
| February 09, 2024 | 3.272 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
2.235
Minimum
Oct 30 2023
8.039
Maximum
Aug 27 2021
4.781
Average
4.162
Median
Price to Book Value Benchmarks
| Roche Holding AG | 5.756 |
| AC Immune SA | 1.272 |
| CRISPR Therapeutics AG | 2.633 |
| Addex Therapeutics Ltd | 13.96 |
| NLS Pharmaceutics Ltd | -- |
Price to Book Value Related Metrics
| PE Ratio | 58.32 |
| PS Ratio | 5.668 |
| Price | 57.93 |
| Earnings Yield | 1.71% |
| Market Cap | 41.78B |
| Operating PE Ratio | 43.76 |
| Normalized PE Ratio | 58.10 |